Sandu Pharmaceuticals share news and announcements
BSE: 524703Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹33.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹33 Cr3,677th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 18.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 5 May 2026
- 0.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 4.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 5.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 5 May 2026
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,719
Sandu Pharmaceuticals share news and announcements
659 announcements, routine notices left out, newest first. Page 3 of 14.
Feb 2025
13 Feb · Management
13 Feb · Standalone Unaudited Financials For Q Ended 31.12.2024
11 Feb · Announcement Under Reg 30 Of SEBI (LODR)-Update-Intimation Inrespect Of The Order Received From Government Of Maharashtra Department Of Goods And Service Tax
4 Feb · Board meeting
Meeting on 13 Feb 2025: quarterly results3 Feb · Announcement Under Reg 30(LODR)-Update Intimation For Change In The Domain Name And Generic Email Id Of The Registrar And Share Transfer Agent ('RTA')
Jan 2025
21 Jan · Announcement Under Regulation 30-Update(Intimation Inrespect Of The Order Received From Department Of Commercial Taxes, Government Of Goa)
2 Jan · Announcement Under Reg 30-Update-Change Of The Name Of Company's RTA
Nov 2024
22 Nov · Announcement Under Regulation 30 Order To Drop Proceeding In Respect Of Return After Scrutiny For The Financial Year 2020-2021 Under Section 61 Of CGST Act .
4 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results
Oct 2024
16 Oct · Notice For Intimating Discrepancies In The Return After Scrutiny For The Financial Year 2020-2021 Under Section 61 Of CGST ACT 2017
Sep 2024
30 Sep · Meeting
Aug 2024
12 Aug · Dividend
12 Aug · Corporate action
12 Aug · Intimation Of Comments Made By Board Of Directors On Non-Compliance With Delayed Submission Of Financials For Year Ended 31St March 2024
12 Aug · Management
12 Aug · Board meeting
5 Aug · Board meeting
Meeting on 12 Aug 2024: final dividend and quarterly results
Jun 2024
29 Jun · Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 As Amended ('SEBI Listing Regulations')-Fines As Per SEBI Circular No. SEBI/HO/CFD/Pod2/CIR/P/2023/ 120 Dated July 11, 2023 (Chapter-VII(A)
5 Jun · Board meeting
May 2024
31 May · Board meeting
Meeting on 5 Jun 2024: audited results30 May · Board meeting